An open-label pilot study of pregabalin pharmacotherapy for alcohol use disorder

References

• Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, Charlson FJ, Norman RE, Flaxman AD, Johns N, et al. Global burden of disease attributable to mental and substance use disorders: findings from the global burden of disease study 2010. Lancet. 2013;382:1575–86.
   PubMed Web of Science ®Google Scholar
• Walker JR, Korte JE, McRae-Clark AL, Hartwell KJ. Adherence across FDA-approved medications for alcohol use disorder in a veterans administration population. J Stud Alcohol Drugs. 2019;80:572–77.
   PubMed Web of Science ®Google Scholar
• Rubinsky AD, Chen C, Batki SL, Williams EC, Harris AHS. Comparative utilization of pharmacotherapy for alcohol use disorder and other psychiatric disorders among U.S. veterans health administration patients with dual diagnoses. J Psychiatr Res. 2015;69:150–57.
   PubMed Web of Science ®Google Scholar
• Kranzler HR, Soyka M. Diagnosis and pharmacotherapy of alcohol use disorder: a review. JAMA. 2018;320:815–24. doi:10.1001/jama.2018.11406.
   PubMed Web of Science ®Google Scholar
• Kranzler HR, Feinn R, Morris P, Hartwell EE. A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder. Addiction. 2019;114:1547–55.
   PubMed Web of Science ®Google Scholar
• Leung JG, Hall-Flavin D, Nelson S, Schmidt KA, Schak KM. The role of gabapentin in the management of alcohol withdrawal and dependence. Ann Pharmacother. 2015;49:897–906.
   PubMed Web of Science ®Google Scholar
• Blodgett JC, Del Re AC, Maisel NC, Finney JW. A meta-analysis of topiramate’s effects for individuals with alcohol use disorders. Alcohol Clin Exp Res. 2014;38:1481–88.
   PubMed Web of Science ®Google Scholar
• Pierce M, Sutterland A, Beraha EM, Morley K, Van Den Brink W. Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: a systematic review and meta-analysis. Eur Neuropsychopharmacol. 2018;28:795–806.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Mechanism of action of alpha2delta ligands: voltage sensitive calcium channel (VSCC) modulators. J Clin Psychiatry. 2004;65:1033–34. doi:10.4088/JCP.v65n0801.
   PubMed Web of Science ®Google Scholar
• Mariani JJ, Rosenthal RN, Tross S, Singh P, Anand OP. A randomized, open-label, controlled trial of gabapentin and phenobarbital in the treatment of alcohol withdrawal. Am J Addict. 2006;15:76–84.
   PubMed Web of Science ®Google Scholar
• Myrick H, Malcolm R, Randall PK, Boyle E, Anton RF, Becker HC, Randall CL. A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. Alcohol Clin Exp Res. 2009;33:1582–88.
   PubMed Web of Science ®Google Scholar
• Trevisan LA, Ralevski E, Keegan K, Oville A, Vuppalapati D, Gonzalez G, Limoncelli D, Petrakis IL. Alcohol detoxification and relapse prevention using valproic acid versus gabapentin in alcohol-dependent patients. Addict Disord Their Treat. 2008;7:119–28.
   Google Scholar
• Furieri FA, Nakamura-Palacios EM. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2007;68:1691–700. doi:10.4088/JCP.v68n1108.
   PubMed Web of Science ®Google Scholar
• Brower KJ, Myra Kim H, Strobbe S, Karam-Hage MA, Consens F, Zucker RA. A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. Alcohol Clin Exp Res. 2008;32:1429–38.
   PubMed Web of Science ®Google Scholar
• Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med. 2014;174:70–77.
   PubMed Web of Science ®Google Scholar
• Chompookham P, Rukngan W, Nilaban S, Suwanmajo S, Yoosom P, Kalayasiri R. A randomized trial of low-dose gabapentin for post hospitalization relapse prevention in a Thai clinical sample of alcohol dependence. Psychiatry Res. 2018;270:34–40.
   PubMed Web of Science ®Google Scholar
• Falk DE, Ryan ML, Fertig JB, Devine EG, Cruz R, Brown ES, Burns H, Salloum IM, Newport DJ, Mendelson J, et al. Gabapentin enacarbil extended-release for alcohol use disorder: a randomized, double-blind, placebo-controlled, multisite trial assessing efficacy and safety. Alcohol Clin Exp Res. 2019;43:158–69.
   PubMed Web of Science ®Google Scholar
• Anton RF, Latham P, Voronin K, Book S, Hoffman M, Prisciandaro J, Bristol E. Efficacy of gabapentin for the treatment of alcohol use disorder in patients with alcohol withdrawal symptoms: a randomized clinical trial. JAMA Intern Med. 2020;180:728.
   PubMed Web of Science ®Google Scholar
• Pfizer. Pregabalin prescribing information. FDA; 2020.
   Google Scholar
• Becker HC, Myrick H, Veatch LM. Pregabalin is effective against behavioral and electrographic seizures during alcohol withdrawal. Alcohol Alcohol. 2006;41:399–406. doi:10.1093/alcalc/agl029.
   PubMed Web of Science ®Google Scholar
• Di Nicola M, Martinotti G, Tedeschi D, Frustaci A, Mazza M, Sarchiapone M, Pozzi G, Bria P, Janiri L. Pregabalin in outpatient detoxification of subjects with mild-to-moderate alcohol withdrawal syndrome. Hum Psychopharmacol. 2010;25:268–75.
   PubMed Web of Science ®Google Scholar
• Martinotti G, Di Nicola M, Frustaci A, Romanelli R, Tedeschi D, Guglielmo R, Guerriero L, Bruschi A, De Filippis R, Pozzi G, et al. Pregabalin, tiapride and lorazepam in alcohol withdrawal syndrome: a multi-centre, randomized, single-blind comparison trial. Addiction. 2010;105:288–99.
   PubMed Web of Science ®Google Scholar
• Forg A, Hein J, Volkmar K, Winter M, Richter C, Heinz A, Müller CA. Efficacy and safety of pregabalin in the treatment of alcohol withdrawal syndrome: a randomized placebo-controlled trial. Alcohol Alcohol. 2012;47:149–55.
   PubMed Web of Science ®Google Scholar
• Martinotti G, Di Nicola M, Tedeschi D, Andreoli S, Reina D, Pomponi M, Mazza M, Romanelli R, Moroni N, De Filippis R, et al. Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial. J Psychopharmacol. 2010;24:1367–74.
   PubMed Web of Science ®Google Scholar
• Pande AC, Feltner DE, Jefferson JW, Davidson JRT, Pollack M, Stein MB, Lydiard RB, Futterer R, Robinson P, Slomkowski M, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol. 2004;24:141–49.
   PubMed Web of Science ®Google Scholar
• Bandelow B, Zohar J, Hollander E, Kasper S, Mӧller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revision. World J Biol Psychiatry. 2008;9:248–312.
   PubMed Web of Science ®Google Scholar
• Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010;49:661–69.
   PubMed Web of Science ®Google Scholar
• Stewart BH, Kugler AR, Thompson PR, Bockbrader HN. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res. 1993;10:276–81.
   PubMed Web of Science ®Google Scholar
• Bockbrader HN, Radulovic LL, Posvar EL, Strand JC, Alvey CW, Busch JA, Randinitis EJ, Corrigan BW, Haig GM, Boyd RA, et al. Clinical pharmacokinetics of pregabalin in healthy volunteers. J Clin Pharmacol. 2010;50:941–50.
   PubMed Web of Science ®Google Scholar
• Myrick H, Brady KT, Malcolm R. New developments in the pharmacotherapy of alcohol dependence. Am J Addict. 2001;10:3–15. doi:10.1080/10550490190942470.
   Web of Science ®Google Scholar
• Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59:22–33;quiz 34–57.
   PubMed Web of Science ®Google Scholar
• Group TCSR. Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods. Alcohol Clin Exp Res. 2003;27:1107–22.
   PubMed Web of Science ®Google Scholar
• Pettinati HM, Weiss RD, Dundon W, Miller WR, Donovan D, Ernst DB, Rounsaville BJ. A structured approach to medical management: a psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence. J Stud Alcohol Suppl. 2005;170–8; discussion 168–9. doi:10.15288/jsas.2005.s15.170.
   Google Scholar
• Guy W. ECDEU assessment manual for psychopharmacology. Rockville (MD): US Department of Health, Education, and Welfare; 1976.
   Google Scholar
• Litten R, Allen J. Measuring alcohol consumption: psychosocial and biochemical methods. Totowa (NJ): The Humana Press Inc; 1992. 41–72 p.
   Google Scholar
• Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict. 1989;84:1353–57.
   PubMedGoogle Scholar
• Johnson BA, Ait-Daoud N, Roache JD. The COMBINE SAFTEE: a structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field. J Stud Alcohol Suppl. 2005;157–67; discussion 140. doi:10.15288/jsas.2005.s15.157.
   PubMedGoogle Scholar